Key points are not available for this paper at this time.
Strategic collaboration among countries and sectors on policies that prioritise equity throughout the full medicine life cycle could make innovative therapies more affordable and accessible globally, argue Krista Kruja and colleagues
Kruja et al. (Tue,) studied this question.